Japanese Journal of Thrombosis and Hemostasis
Online ISSN : 1880-8808
Print ISSN : 0915-7441
ISSN-L : 0915-7441
Search
Advanced search
OR
Browse
Search
Volume 16, Issue 4
Displaying 1-11 of 11 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Reviews
Original Article
  • Beneficial effects of beraprost sodium on the LPS-induced rat DIC model with special reference to hemostatic markers and cytokine levels
    Anna KUBO, Hidesaku ASAKURA, Mika OMOTE, Masahisa ARAHATA, Yasuko KADO ...
    2005 Volume 16 Issue 4 Pages 372-377
    Published: 2005
    Released on J-STAGE: May 15, 2007
    DOIhttps://doi.org/10.2491/jjsth.16.372
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We have elucidated the effect of a PGI2 derivative, beraprost sodium (BPS), against the lipopolysaccharide (LPS)-induced disseminated intravascular coagulation (DIC) model in rats. DIC was induced in the Wistar strain male rats by administering LPS at 5.0 mg/kg of body weight via their tail vein over a period of 4 hours. The effect of BPS on the LPS-induced DIC was observed by continuous administration of BPS at 0.2 mg/kg/4.5hr, which had been started 30 minutes prior to the LPS administration. The decreased platelet counts and plasma fibrinogen and the increased thrombin-antithrombin complex and D-dimer, which had been generally noted in these animal models, were all significantly attenuated. Liver and renal failures were considerably ameliorated. Moreover, the increase in plasma levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) was significantly reduced by BPS in the LPS-induced DIC model. From these results, we conclude that BPS was able to exert suppression of DIC together with inhibition of the production of inflammatory cytokines in the LPS-induced DIC model.
    View full abstract
    Download PDF (620K)
  • Discrepancy in the aPS/PT-IgG titers using 2 ELISA kits in patients with several kinds of collagen diseases
    Yohei KAWASHIMA, Masahide YAMAZAKI, Eriko MORISHITA, Hidesaku ASAKURA, ...
    2005 Volume 16 Issue 4 Pages 378-385
    Published: 2005
    Released on J-STAGE: May 15, 2007
    DOIhttps://doi.org/10.2491/jjsth.16.378
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    ELISA kits for the measurement of phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) have recently been developed by two companies, MBL Corporation and Cosmic Corporation, in Japan. We evaluated the relationship between aPS/PT titers using these two ELISA kits in patients with systemic lupus erythematosus (SLE), primary antiphospholipid syndrome (PAPS) and systemic scleroderma (SSc). Namely, Cosmic aPS/PT titers were found to be significantly correlated with MBL aPS/PT titers in patients with SLE and PAPS, but not so in patients with SSc(r=0.99, 0.99, and 0.07, p<0.0001, <0.0001, and NS, respectively). The results suggest that commercially available aPS/PT ELISA kits lead to different results and thus, we should pay attention to the clinical significance of aPS/PT titers in certain patients associated with a variety of underlying diseases such as SSc.
    View full abstract
    Download PDF (603K)
Technical Lecture
Topics
Mitsubishi Pharma Research Foundation Forum
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top